Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03028441 · ClinicalTrials.gov registry record · Phase 1
Phase I Trial of Measles Vectored Chikungungya Vaccine
A Phase 1 study of Chikungunya Virus Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
- 3
- Study locations
NCT03028441: Completed Phase 1 study of Chikungunya Virus Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT03028441 is a Phase 1 study of Chikungunya Virus Infection that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 180 participants, below the 413-participant average among 4 other Chikungunya Virus Infection trials with a reported enrollment target (56% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03028441, a Phase 1 study of Chikungunya Virus Infection, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is a randomized, double-blinded, Phase 1, placebo- controlled, and dose comparison trial to evaluate the safety, immunogenicity and schedule of MV-CHIK. Two dosage levels and 3 immunization schedules will be evaluated. This study will enroll up to 180 healthy subjects aged 18 to 45 years.Study duration is approximately 22 months. Subject participation duration is approximately 8-13 months. The primary objectives are to evaluate the safety and tolerability of 5 x 10\^4 TCID50 and 5 x 10\^5 TCID50 MV-CHIK and placebo following two consecutive intramuscular injections and to assess the CHIKV serum plaque reduction neutralization test (PRNT50) antibody responses to 5 x 10\^4 TCID50, 5 x 10\^5 TCID50 of MV-CHIK or placebo on day 29 following the first dose.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL VRC-CHKVLP059-00-VP
Study Locations (3)
Georgia
- Emory Children's Center - Pediatric Infectious Diseases - Atlanta
Iowa
- University of Iowa - Vaccine Research and Education Unit - Iowa City
Texas
- Baylor College of Medicine - Molecular Virology and Microbiology - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2017-05-30 |
| Est. Completion | 2019-01-17 |
| Phase | Phase 1 |
What the finished NCT03028441 record still lists
NCT03028441 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 413-participant average among 4 other Chikungunya Virus Infection trials with a reported enrollment target (56% lower).
The record links to 1 condition, with Chikungunya Virus Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03028441 reports a single indexed study location in Georgia, Iowa, Texas.
Frequently Asked Questions
What is clinical trial NCT03028441 about?
NCT03028441 is a clinical study titled "Phase I Trial of Measles Vectored Chikungungya Vaccine". This study is a randomized, double-blinded, Phase 1, placebo- controlled, and dose comparison trial to evaluate the safety, immunogenicity and schedule of MV-CHIK. Two dosage levels and 3 immunization schedules will be evaluated. This study will enroll up to 180 healthy subjects aged 18 to 45 years....
What is the current status of trial NCT03028441?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2017-05-30. Estimated completion is 2019-01-17.
What conditions does trial NCT03028441 study?
This clinical trial studies the following conditions: Chikungunya Virus Infection.
What interventions are being tested in trial NCT03028441?
The interventions under investigation include: Placebo (OTHER), VRC-CHKVLP059-00-VP (BIOLOGICAL).
Who is sponsoring clinical trial NCT03028441?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03028441 being conducted?
This trial has 3 study locations across Georgia, Iowa, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chikungunya Virus Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Study of SAR440894 vs Placebo
COMPLETED · Phase 1
-
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination
ACTIVE NOT RECRUITING · Phase 3
-
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)
ACTIVE NOT RECRUITING · Phase 3
-
Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI